Materias dentro de su búsqueda.
Mostrando 2,541 - 2,560 Resultados de 58,773 Para Buscar '"Her"', tiempo de consulta: 0.54s Limitar resultados
  1. 2541
    por Tran, Phuong T., Diaby, Vakaramoko
    Publicado 2020
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Cost-Effectiveness Analysis of Adjuvant Neratinib Following Trastuzumab in Early-Stage HER2-Positive Breast Cancer
  2. 2542
    “…EXPERIMENTAL DESIGN: Eligibility for this pilot phase I trial included patients with localized HER2-negative breast cancer who received systemic nivolumab and ipilimumab and intratumor talimogene laherparepvec (T-VEC; NCT04185311). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    A Pilot Study of Neoadjuvant Nivolumab, Ipilimumab, and Intralesional Oncolytic Virotherapy for HER2-negative Breast Cancer
  3. 2543
    “…METHOD: Patients with stages II and III HER2-negative primary breast cancer who received neoadjuvant chemotherapy followed by definitive surgery were categorized according to their ER percentages into three groups: ER-negative, ER low positive, and ER > 10% positive. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Impact of estrogen receptor expression level on response to neoadjuvant chemotherapy and prognosis in HER2-negative breast cancers
  4. 2544
    “…In this study, we targeted EZH2 and HER2/neu-EGFR, both of which are related to cell proliferation and overexpression-induced tumors. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Dual Targeting of EZH2 Degradation and EGFR/HER2 Inhibition for Enhanced Efficacy against Burkitt’s Lymphoma
  5. 2545
    “…Consequently, the complex improved photothermal and chemotherapy treatment efficacy in HER2-positive cells in vitro and a subcutaneous tumor model in vivo, while minimized harm to normal cells and showed desirable organ compatibility. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    HER2-targeting two-dimensional black phosphorus as a nanoplatform for chemo-photothermal therapy in breast cancer
  6. 2546
    “…HER2 is an important prognostic marker in breast cancer (BC) patients, which also plays a crucial role in their therapeutic plan. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Tumor characteristics and survival rate of HER2-low breast cancer patients: a retrospective cohort study
  7. 2547
    “…Altogether, we demonstrated the impact of genomic (co‐)alterations on outcomes with one of the largest clinico‐genomic datasets of ER+, HER2−, PIK3CAmut breast cancer patients treated with a PI3K inhibitor.…”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    ER+, HER2− advanced breast cancer treated with taselisib and fulvestrant: genomic landscape and associated clinical outcomes
  8. 2548
    “…A HEK 293 cell line transfected to produce soluble HER1 receptor was used. The bioreactor was operated at three different dilution rates in sequential manner. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    HEK293 producing the extracellular domain HER1: Full datasets of continuous fermentation process and metabolites analysis
  9. 2549
    “…HER2-positive breast cancer (BC) invasiveness and drug-resistance issue is the critical treatment obstacle recently. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Phosphorylation of EZH2 differs HER2-positive breast cancer invasiveness in a site-specific manner
  10. 2550
    “…Background: There are multiple genes that are co-amplified along with human epidermal growth factor receptor 2 (HER2) in chromosome 17. GRB7 and PGAP3 are two such genes. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Detecting Human Epidermal Growth Factor Receptor 2 (HER2) Amplification: Proof of Concept of an Alternative Approach
  11. 2551
    “…BACKGROUND: Prolonged treatment of HER2+ breast cancer with lapatinib (LAP) causes cellular senescence and acquired drug resistance, which often associating with poor prognosis for patients. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Dynamic ultrasound molecular‐targeted imaging of senescence in evaluation of lapatinib resistance in HER2‐positive breast cancer
  12. 2552
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Next-generation antibody–drug conjugates revolutionize the precise classification and treatment of HER2-expressing breast cancer
  13. 2553
    por Majumder, Avisek
    Publicado 2023
    “…Human epidermal growth factor receptor 3 (HER3) is the only family member of the EGRF/HER family of receptor tyrosine kinases that lacks an active kinase domain (KD), which makes it an obligate binding partner with other receptors for its oncogenic role. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    HER3: Toward the Prognostic Significance, Therapeutic Potential, Current Challenges, and Future Therapeutics in Different Types of Cancer
  14. 2554
    por Hurst, Helen C
    Publicado 2001
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Texto
    Update on HER-2 as a target for cancer therapy: The ERBB2 promoter and its exploitation for cancer treatment
  15. 2555
    “…METHODS: Among 181 node-negative breast cancer (NNBC) patients, c-myc and HER-2/neu oncogenes were identified prospectively using double differential PCR. …”
    Enlace del recurso
    Enlace del recurso
    Texto
    C-myc, not HER-2/neu, can predict recurrence and mortality of patients with node-negative breast cancer
  16. 2556
    por Witton, Caroline J
    Publicado 2003
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Texto
    Structure of HER receptors and intracellular localisation of downstream effector elements gives insight into mechanism of tumour growth promotion
  17. 2557
    Enlace del recurso
    Enlace del recurso
    Texto
    Complete pathological response in patients with locally advanced cancer of breast and positive Her2/neu with neoadjuvant chemotherapy
  18. 2558
    “…Gene amplification and/or somatic mutations of the HER2/Neu (ErbB2) proto-oncogene occur in approximately 20% of breast cancers. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Texto
    A mathematical model separates quantitatively the cytostatic and cytotoxic effects of a HER2 tyrosine kinase inhibitor
  19. 2559
    “…Two human cell lines (UACC-812 and 893), both containing significant amplification of the HER-2/neu gene, were established from biopsy specimens of breast carcinomas. …”
    Enlace del recurso
    Enlace del recurso
    Texto
    Establishment of two new cell lines derived from human breast carcinomas with HER-2/neu amplification.
  20. 2560
    “…In vitro, diabodies produced from the anti-HER2/neu (c-erbB-2) scFv C6.5 displayed approximately 40-fold greater affinity for HER2/neu by surface plasmon resonance biosensor measurements and significantly prolonged association with antigen on the surface of SK-OV-3 cells (t1/2 cell surface retention of > 5 h vs 5 min) compared with C6.5 scFv. …”
    Enlace del recurso
    Enlace del recurso
    Texto
    Prolonged in vivo tumour retention of a human diabody targeting the extracellular domain of human HER2/neu.
Herramientas de búsqueda: RSS